XXE5XY9
XXE5XY9 — Measurement of Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology, New Technology Group 9
Billable / specific codeICD-10-PCS
CMS abbreviated title: Measure Pos Bld/Isol Colonies Bimod Pheno Susc New Tech 9
How XXE5XY9 is built
Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.
- XSectionNew Technology — What family of procedure this is
- XBody systemWhich system it acts on
- ERoot operationThe objective — the verb of the procedure
- 5Body partThe specific site
- XApproachHow the site was reached
- YDeviceWhat was left in place, if anything
- 9QualifierA further distinction where one applies
Codes near XXE5XY9
In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.
- XXE5X2AMeasurement of Infection, Phenotypic Fully Automated Rapid Susceptibility Technology with Controlled Inoculum, New Technology Group 10
- XXE5X38Measurement of Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction, New Technology Group 8
- XXE5X4AMeasurement of Infection, Positive Blood Culture Small Molecule Sensor Array Technology, New Technology Group 10
- XXE5X5AMeasurement of Immune Response, Whole Blood Cellular Assessment via Microfluidic Deformability, New Technology Group 10
- XXE5XBBMeasurement of Infection and Immune Response, Gene Expression Testing System, New Technology Group 11
- XXE5XR7Measurement of Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, New Technology Group 7
- XXE5XT7Measurement of Intracranial Arterial Flow, Whole Blood mRNA, New Technology Group 7
- XXE5XV7Measurement of Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection, New Technology Group 7
- XXE5XY9Measurement of Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology, New Technology Group 9
- XXE97U7Measurement of Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction, New Technology Group 7
- XXEZXABMeasurement of Macronutrient Content, Computer-aided Assessment for Nutrition Management, New Technology Group 11
- XXEZXCBMeasurement of Infection, Computer-aided Triage and Notification, New Technology Group 11
- XY0VX83Extracorporeal Introduction of Endothelial Damage Inhibitor to Vein Graft, New Technology Group 3
- XY0YX28Extracorporeal Introduction of Taurolidine Anti-infective and Heparin Anticoagulant, New Technology Group 8
- XY0YX37Extracorporeal Introduction of Nafamostat Anticoagulant, New Technology Group 7